Loading…
Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer
To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer. We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of bloo...
Saved in:
| Published in: | Future oncology (London, England) England), 2019-10, Vol.15 (28), p.3233-3242 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c371t-2134a8d876188a0eaf8a56fcda8380ee6de079479a9bc3a997d4ea190a71f02b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c371t-2134a8d876188a0eaf8a56fcda8380ee6de079479a9bc3a997d4ea190a71f02b3 |
| container_end_page | 3242 |
| container_issue | 28 |
| container_start_page | 3233 |
| container_title | Future oncology (London, England) |
| container_volume | 15 |
| creator | Li, Aijie He, Kewen Guo, Dong Liu, Chao Wang, Duoying Mu, Xiangkui Yu, Jinming |
| description | To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer.
We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of blood biomarkers. The outcome was defined by the pathologic complete response and good response.
Carcinoembryonic antigen (CEA) (p |
| doi_str_mv | 10.2217/fon-2019-0389 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2268310299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2268310299</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-2134a8d876188a0eaf8a56fcda8380ee6de079479a9bc3a997d4ea190a71f02b3</originalsourceid><addsrcrecordid>eNp1kUtrFjEUhoMo9qJLtxJw4yaaWyfJUj6qFgqK1HXIJGdsamYyJhml_94MX3UhuEoOPHk5eR-EXjD6hnOm3k55IZwyQ6jQ5hE6ZUpKogVlj_tdKkOGwcgTdFbrHaVSiQv6FJ0IJpTgXJyi7XOBVsC1GZaGx5RzwGPMsyvfoVS8FgjRN7y6dptT_hY9LlDXvFSouGW8QCaHLzc4LjsSe0bFv2K7xSl7l9I9duGnWzyE_sw3l7Dfp_IMPZlcqvD84TxHX99f3hw-kutPH64O766JF4o1wpmQTgetBqa1o-Am7S6GyQenhaYAQwCqTP-kM6MXzhgVJDhmqFNsonwU5-j1MXct-ccGtdk5Vg8pub74Vi3ngxaMcmM6-uof9C5vZenbWS6VVIwOhnWKHClfcq0FJruW2Mu6t4za3YftPuzuw-4-Ov_yIXUbZwh_6T8COmCOwLS1rVfre4ce7HGa9_LjAv8J_w0VUZs3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2474710691</pqid></control><display><type>article</type><title>Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer</title><source>PubMed Central</source><creator>Li, Aijie ; He, Kewen ; Guo, Dong ; Liu, Chao ; Wang, Duoying ; Mu, Xiangkui ; Yu, Jinming</creator><creatorcontrib>Li, Aijie ; He, Kewen ; Guo, Dong ; Liu, Chao ; Wang, Duoying ; Mu, Xiangkui ; Yu, Jinming</creatorcontrib><description>To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer.
We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of blood biomarkers. The outcome was defined by the pathologic complete response and good response.
Carcinoembryonic antigen (CEA) (p < 0.001), neutrophil-to-lymphocyte ratio (p = 0.024), platelet-to-lymphocyte ratio (p = 0.006) and lymphocyte-to-monocyte ratio (LMR) (p < 0.001) were significant predictors of pathologic complete response, with area under the curve of 0.785, 0.794, 0.740 and 0.913, respectively; CEA (p = 0.007) and LMR (p < 0.001) correlated significantly with good response, with area under the curve of 0.743 and 0.771, respectively.
Lower LMR and higher CEA, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before treatment could predict poorer pathologic response to neo-CRT in patients with locally advanced rectal cancer.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2019-0389</identifier><identifier>PMID: 31373223</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers ; Biomarkers, Tumor - analysis ; Blood diseases ; Blood platelets ; Cancer therapies ; Capecitabine - administration & dosage ; carcinoembryonic antigen ; Carcinoembryonic Antigen - metabolism ; Chemoradiotherapy - mortality ; Chemotherapy ; Colorectal cancer ; DNA methylation ; Female ; Fluorouracil - administration & dosage ; Follow-Up Studies ; Gene expression ; GPI-Linked Proteins - metabolism ; Hospitals ; Humans ; Inflammation ; Laboratories ; Leucovorin - administration & dosage ; Lymphatic system ; lymphocyte-to-monocyte ratio ; Lymphocytes ; Lymphocytes - pathology ; Male ; Metastasis ; Middle Aged ; neoadjuvant chemoradiotherapy ; Neoadjuvant Therapy - mortality ; neutrophil-to-lymphocyte ratio ; Neutrophils ; Neutrophils - pathology ; Oxaliplatin - administration & dosage ; pathologic response ; Patients ; platelet-to-lymphocyte ratio ; predictor ; Prognosis ; Radiation therapy ; rectal cancer ; Rectal Neoplasms - blood ; Rectal Neoplasms - metabolism ; Rectal Neoplasms - pathology ; Rectal Neoplasms - therapy ; Retrospective Studies ; ROC Curve ; Surgery ; Survival Rate ; Young Adult</subject><ispartof>Future oncology (London, England), 2019-10, Vol.15 (28), p.3233-3242</ispartof><rights>2019 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Oct 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-2134a8d876188a0eaf8a56fcda8380ee6de079479a9bc3a997d4ea190a71f02b3</citedby><cites>FETCH-LOGICAL-c371t-2134a8d876188a0eaf8a56fcda8380ee6de079479a9bc3a997d4ea190a71f02b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31373223$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Aijie</creatorcontrib><creatorcontrib>He, Kewen</creatorcontrib><creatorcontrib>Guo, Dong</creatorcontrib><creatorcontrib>Liu, Chao</creatorcontrib><creatorcontrib>Wang, Duoying</creatorcontrib><creatorcontrib>Mu, Xiangkui</creatorcontrib><creatorcontrib>Yu, Jinming</creatorcontrib><title>Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer.
We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of blood biomarkers. The outcome was defined by the pathologic complete response and good response.
Carcinoembryonic antigen (CEA) (p < 0.001), neutrophil-to-lymphocyte ratio (p = 0.024), platelet-to-lymphocyte ratio (p = 0.006) and lymphocyte-to-monocyte ratio (LMR) (p < 0.001) were significant predictors of pathologic complete response, with area under the curve of 0.785, 0.794, 0.740 and 0.913, respectively; CEA (p = 0.007) and LMR (p < 0.001) correlated significantly with good response, with area under the curve of 0.743 and 0.771, respectively.
Lower LMR and higher CEA, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before treatment could predict poorer pathologic response to neo-CRT in patients with locally advanced rectal cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Blood diseases</subject><subject>Blood platelets</subject><subject>Cancer therapies</subject><subject>Capecitabine - administration & dosage</subject><subject>carcinoembryonic antigen</subject><subject>Carcinoembryonic Antigen - metabolism</subject><subject>Chemoradiotherapy - mortality</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>DNA methylation</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Follow-Up Studies</subject><subject>Gene expression</subject><subject>GPI-Linked Proteins - metabolism</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Laboratories</subject><subject>Leucovorin - administration & dosage</subject><subject>Lymphatic system</subject><subject>lymphocyte-to-monocyte ratio</subject><subject>Lymphocytes</subject><subject>Lymphocytes - pathology</subject><subject>Male</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>neoadjuvant chemoradiotherapy</subject><subject>Neoadjuvant Therapy - mortality</subject><subject>neutrophil-to-lymphocyte ratio</subject><subject>Neutrophils</subject><subject>Neutrophils - pathology</subject><subject>Oxaliplatin - administration & dosage</subject><subject>pathologic response</subject><subject>Patients</subject><subject>platelet-to-lymphocyte ratio</subject><subject>predictor</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>rectal cancer</subject><subject>Rectal Neoplasms - blood</subject><subject>Rectal Neoplasms - metabolism</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - therapy</subject><subject>Retrospective Studies</subject><subject>ROC Curve</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kUtrFjEUhoMo9qJLtxJw4yaaWyfJUj6qFgqK1HXIJGdsamYyJhml_94MX3UhuEoOPHk5eR-EXjD6hnOm3k55IZwyQ6jQ5hE6ZUpKogVlj_tdKkOGwcgTdFbrHaVSiQv6FJ0IJpTgXJyi7XOBVsC1GZaGx5RzwGPMsyvfoVS8FgjRN7y6dptT_hY9LlDXvFSouGW8QCaHLzc4LjsSe0bFv2K7xSl7l9I9duGnWzyE_sw3l7Dfp_IMPZlcqvD84TxHX99f3hw-kutPH64O766JF4o1wpmQTgetBqa1o-Am7S6GyQenhaYAQwCqTP-kM6MXzhgVJDhmqFNsonwU5-j1MXct-ccGtdk5Vg8pub74Vi3ngxaMcmM6-uof9C5vZenbWS6VVIwOhnWKHClfcq0FJruW2Mu6t4za3YftPuzuw-4-Ov_yIXUbZwh_6T8COmCOwLS1rVfre4ce7HGa9_LjAv8J_w0VUZs3</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Li, Aijie</creator><creator>He, Kewen</creator><creator>Guo, Dong</creator><creator>Liu, Chao</creator><creator>Wang, Duoying</creator><creator>Mu, Xiangkui</creator><creator>Yu, Jinming</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20191001</creationdate><title>Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer</title><author>Li, Aijie ; He, Kewen ; Guo, Dong ; Liu, Chao ; Wang, Duoying ; Mu, Xiangkui ; Yu, Jinming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-2134a8d876188a0eaf8a56fcda8380ee6de079479a9bc3a997d4ea190a71f02b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Blood diseases</topic><topic>Blood platelets</topic><topic>Cancer therapies</topic><topic>Capecitabine - administration & dosage</topic><topic>carcinoembryonic antigen</topic><topic>Carcinoembryonic Antigen - metabolism</topic><topic>Chemoradiotherapy - mortality</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>DNA methylation</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Follow-Up Studies</topic><topic>Gene expression</topic><topic>GPI-Linked Proteins - metabolism</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Laboratories</topic><topic>Leucovorin - administration & dosage</topic><topic>Lymphatic system</topic><topic>lymphocyte-to-monocyte ratio</topic><topic>Lymphocytes</topic><topic>Lymphocytes - pathology</topic><topic>Male</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>neoadjuvant chemoradiotherapy</topic><topic>Neoadjuvant Therapy - mortality</topic><topic>neutrophil-to-lymphocyte ratio</topic><topic>Neutrophils</topic><topic>Neutrophils - pathology</topic><topic>Oxaliplatin - administration & dosage</topic><topic>pathologic response</topic><topic>Patients</topic><topic>platelet-to-lymphocyte ratio</topic><topic>predictor</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>rectal cancer</topic><topic>Rectal Neoplasms - blood</topic><topic>Rectal Neoplasms - metabolism</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - therapy</topic><topic>Retrospective Studies</topic><topic>ROC Curve</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Aijie</creatorcontrib><creatorcontrib>He, Kewen</creatorcontrib><creatorcontrib>Guo, Dong</creatorcontrib><creatorcontrib>Liu, Chao</creatorcontrib><creatorcontrib>Wang, Duoying</creatorcontrib><creatorcontrib>Mu, Xiangkui</creatorcontrib><creatorcontrib>Yu, Jinming</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Aijie</au><au>He, Kewen</au><au>Guo, Dong</au><au>Liu, Chao</au><au>Wang, Duoying</au><au>Mu, Xiangkui</au><au>Yu, Jinming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>15</volume><issue>28</issue><spage>3233</spage><epage>3242</epage><pages>3233-3242</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer.
We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of blood biomarkers. The outcome was defined by the pathologic complete response and good response.
Carcinoembryonic antigen (CEA) (p < 0.001), neutrophil-to-lymphocyte ratio (p = 0.024), platelet-to-lymphocyte ratio (p = 0.006) and lymphocyte-to-monocyte ratio (LMR) (p < 0.001) were significant predictors of pathologic complete response, with area under the curve of 0.785, 0.794, 0.740 and 0.913, respectively; CEA (p = 0.007) and LMR (p < 0.001) correlated significantly with good response, with area under the curve of 0.743 and 0.771, respectively.
Lower LMR and higher CEA, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before treatment could predict poorer pathologic response to neo-CRT in patients with locally advanced rectal cancer.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>31373223</pmid><doi>10.2217/fon-2019-0389</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2019-10, Vol.15 (28), p.3233-3242 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2268310299 |
| source | PubMed Central |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Tumor - analysis Blood diseases Blood platelets Cancer therapies Capecitabine - administration & dosage carcinoembryonic antigen Carcinoembryonic Antigen - metabolism Chemoradiotherapy - mortality Chemotherapy Colorectal cancer DNA methylation Female Fluorouracil - administration & dosage Follow-Up Studies Gene expression GPI-Linked Proteins - metabolism Hospitals Humans Inflammation Laboratories Leucovorin - administration & dosage Lymphatic system lymphocyte-to-monocyte ratio Lymphocytes Lymphocytes - pathology Male Metastasis Middle Aged neoadjuvant chemoradiotherapy Neoadjuvant Therapy - mortality neutrophil-to-lymphocyte ratio Neutrophils Neutrophils - pathology Oxaliplatin - administration & dosage pathologic response Patients platelet-to-lymphocyte ratio predictor Prognosis Radiation therapy rectal cancer Rectal Neoplasms - blood Rectal Neoplasms - metabolism Rectal Neoplasms - pathology Rectal Neoplasms - therapy Retrospective Studies ROC Curve Surgery Survival Rate Young Adult |
| title | Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T23%3A42%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20blood%20biomarkers%20predict%20pathologic%20responses%20to%20neo-CRT%20in%20patients%20with%20locally%20advanced%20rectal%20cancer&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Li,%20Aijie&rft.date=2019-10-01&rft.volume=15&rft.issue=28&rft.spage=3233&rft.epage=3242&rft.pages=3233-3242&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2019-0389&rft_dat=%3Cproquest_cross%3E2268310299%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c371t-2134a8d876188a0eaf8a56fcda8380ee6de079479a9bc3a997d4ea190a71f02b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2474710691&rft_id=info:pmid/31373223&rfr_iscdi=true |